These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34023149)

  • 21. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
    Choi WM; Choi J; Wong GL; Han S; Lim YS
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87. PubMed ID: 33444532
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
    Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
    Hsu YC; Ho HJ; Lee TY; Huang YT; Wu MS; Lin JT; Wu CY; El-Serag HB
    J Viral Hepat; 2018 May; 25(5):543-551. PubMed ID: 29193536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
    Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Kim BK; Kim SU
    Hepatology; 2021 Jan; 73(1):466. PubMed ID: 32602169
    [No Abstract]   [Full Text] [Related]  

  • 27. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
    Yuan J; Peng Y; Hao FB; Wang YQ; Wang CR; Zhong GC
    Aging (Albany NY); 2021 Feb; 13(5):7147-7165. PubMed ID: 33658397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Yuan G; Yao J; Yu J; Xie X; He S
    Hepatology; 2021 Mar; 73(3):1240. PubMed ID: 33016343
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Eur J Intern Med; 2022 Sep; 103():122-125. PubMed ID: 35835625
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
    Lampertico P; Papatheodoridis GV
    Aliment Pharmacol Ther; 2021 Mar; 53(5):657-658. PubMed ID: 33566425
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
    Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
    PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
    Boettler T; Thimme R
    Dig Dis; 2015; 33(4):608-12. PubMed ID: 26159281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
    Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
    Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma.
    Roberts SK; Majeed A; Kemp W
    Clin Liver Dis; 2021 Nov; 25(4):785-803. PubMed ID: 34593153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding.
    Dore GJ; Danta M; Matthews GV
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1028-1029. PubMed ID: 33007227
    [No Abstract]   [Full Text] [Related]  

  • 38. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
    Yu JH; Suh YJ; Jin YJ; Heo NY; Jang JW; You CR; An HY; Lee JW
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):865-872. PubMed ID: 30694912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
    Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.